SciSparc shares are trading higher after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.
Portfolio Pulse from Benzinga Newsdesk
SciSparc has received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. This has led to an increase in the company's share price.
October 31, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc's shares are trading higher after the company's patent application for a pain treatment was accepted by the Australian patent office.
The acceptance of SciSparc's patent application by the Australian patent office is a positive development for the company. This could potentially lead to increased revenues from the sale of the patented product, which is reflected in the rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100